Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)

Patients with transplant‐ineligible relapsed and refractory multiple myeloma (RRMM) have a short life expectancy, especially when they have failed both the proteasome inhibitor and immunomodulator therapies. This study aimed to assess the efficacy and safety of pomalidomide, cyclophosphamide, and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ho Sup, Kim, Kihyun, Kim, Seok Jin, Lee, Je‐Jung, Kim, Inho, Kim, Jin Seok, Eom, Hyeon‐Seok, Yoon, Dok Hyun, Suh, Cheolwon, Shin, Ho‐Jin, Mun, Yeung‐Chul, Kim, Min Kyoung, Lim, Sung‐Nam, Choi, Chul Won, Kang, Hye Jin, Yoon, Sung‐Soo, Min, Chang‐Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983889/
https://www.ncbi.nlm.nih.gov/pubmed/31919872
http://dx.doi.org/10.1002/ajh.25726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983889/
https://www.ncbi.nlm.nih.gov/pubmed/31919872
http://dx.doi.org/10.1002/ajh.25726

Ejemplares similares